Search Results - "Dulude, H"

Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study by Bruera, E, Ernst, S, Hagen, N, Spachynski, K, Belzile, M, Hanson, J, Summers, N, Brown, B, Dulude, H, Gallant, G

“…To evaluate the effect of megestrol acetate at a lower dose than previously investigated on the symptoms of cachexia in patients with advanced cancer. A total…”
Get more information

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS) by WARNER, E, GOEL, R, GALLANT, G, CHANG, J, CHOW, W, VERMA, S, DANCEY, J, FRANSSEN, E, DULUDE, H, GIROUARD, M, CORREIA, J

“…Cisplatin-based combination chemotherapy is frequently used to treat patients with carcinoma of unknown primary site (CUPS). Response rates in the literature…”
Get full text

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer by Glück, S, Germond, C, Lopez, P, Cano, P, Dorreen, M, Koski, T, Arnold, A, Dulude, H, Gallant, G

“…The aim of this phase I study was to determine the dose limiting toxicity (DLT), maximum tolerated dose (MTD) and efficacy of a new combination of…”
Get full text

A phase I–II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer by Gelmon, K. A., Tolcher, A., O'Reilly, S., Campbell, C., Bryce, C., Shenkier, T., Ragaz, J., Ayers, D., Nakashima, L., Rielly, S., Dulude, H.

“…Background: Single-agent bi-weekly paclitaxel was studied as first-line metastatic treatment for breast cancer in a phase I–II trial. Patients and methods:…”
Get full text

Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer by Evans, W.K, Earle, C.C, Stewart, D.J, Dahrouge, S, Tomiak, E, Goss, G, Logan, D, Goel, R, Gertler, S.Z, Dulude, H

“…Purpose: To determine the activity, toxicity, and optimal dose of paclitaxel when given by one hour infusion combined with carboplatin in advanced non-small…”
Get full text

Synthesis and preliminary in vitro cytotoxicity evaluation of 1,3-bis-(2-propynyl)-1-nitrosourea (BPNU) and derivatives by Gallant, G, Salvador, R, Dulude, H

“…The in vitro cytotoxicity and differential cellular sensitivity of a series of new N1-(propargyl) nitrosourea derivatives, including…”
Get more information

In vitro cytotoxicity and differential cellular sensitivity of new N-methyl and N-propargyl urea and nitrosourea derivatives of diamino acids against sixty human NCI tumor cell lines by Gallant, G, Salvador, R, Dulude, H

“…The in vitro cytotoxicity and differential cellular sensitivity of a series of new N-methyl and N-propargyl urea and nitrosourea derivatives of diamino acids…”
Get more information

A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis by Nam, Robert K, Reeves, Jonathan R, Toi, Ants, Dulude, Helene, Trachtenberg, John, Emami, Marjan, Daigneault, Luc, Panchal, Chandra, Sugar, Linda, Jewett, Michael A S, Narod, Steven A

“…New biomarkers for prostate cancer are needed. We determined whether a novel serum marker, total PSP94 can be used to accomplish these goals. We conducted a…”
Get more information

A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis by Annabi, Borhane, Bouzeghrane, Mounia, Currie, Jean-Christophe, Hawkins, Robert, Dulude, Hélène, Daigneault, Luc, Ruiz, Marcia, Wisniewski, Jan, Garde, Seema, Rabbani, Shafaat A, Panchal, Chandra, Wu, Jinzi J, Béliveau, Richard

“…PCK3145 is a synthetic peptide corresponding to amino acids 31-45 of prostate secretory protein 94, which can reduce experimental skeletal metastases and…”
Get full text

Prognostic value of serum PSP94 (prostate secretory protein of 94 amino acids) and its binding protein (PSPBP) after radical prostatectomy by Reeves, J. R., Dulude, H., Panchal, C., Daigneault, L., Ramnani, D. M., Xuan, J. W.

“…Abstract only…”
Get full text

Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC)—The US experience by Slovin, S. F., Daigneault, L., Dulude, H., Panchal, C., Richardson, J., Curley, T., Delacruz, A., Fleisher, M., Morris, M., Scher, H.

“…Abstract only 4650 Background: PCK3145 is a synthetic 15-mer peptide derived from the natural sequence of amino acids of Prostate Secretory Protein (PSCP94), a…”
Get full text

Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostatic cancer (HRPC) using serum markers by Daigneault, L., Dulude, H., Panchal, C., Garde, S., Armstrong, A., Cowan, R., Hawkins, R.

“…Abstract only…”
Get full text

A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC) by Hawkins, R., Panchal, C., Dulude, H., Cowan, R., Armstrong, A., Fenemore, J., Daigneault, L.

“…Abstract only…”
Get full text

A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145 administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC) by Hawkins, R., Panchal, C., Dulude, H., Cowan, R., Armstrong, A., Fenemore, J., Daigneault, L.

“…Abstract only…”
Get full text

Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostatic cancer (HRPC) using serum markers by Daigneault, L., Dulude, H., Panchal, C., Garde, S., Armstrong, A., Cowan, R., Hawkins, R.

“…Abstract only…”
Get full text

A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer by Daigneault, L., Panchal, C., Scher, H. I., Slovin, S. F., Rabbani, S., Dulude, H., Garde, S., Ruiz, M., Wu, J., Hawkins, R.

“…Abstract only…”
Get full text

A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer by Kirkbride, P, Gelmon, K, Eisenhauer, E, Fisher, B, Dulude, H

“…The addition of chemotherapy to radical radiotherapy (XRT) has been shown to improve survival in locally advanced nonsmall cell lung cancer (9). Consequently,…”
Get more information

Phase I/II study of biweekly paclitaxel and cisplatin in nonsmall cell lung cancer (NSCLC). Final result with QOL data by Melosky, B, Gelmon, K.A, Murray, N, Page, R, Ayers, D, Lee, C, Reilly, S, Dulude, H

Get full text

NCIC CTG IND102: a phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrent squamous cell carcinoma of the cervix by Trudeau, M., Stuart, G., Hirte, H., Drouin, P., Plante, M., Bessette, P., Dulude, H., Lebwohl, D.

Get full text

In vitro cytotoxicity and differential cellular sensitivity of derivatives of diamino acids. I. N1-methyl, N1-allyl, N1-(2-chloroethyl) and N1-propargyl ureas by Dulude, H, Salvador, R, Gallant, G

“…The in vitro cytotoxicity and differential cellular sensitivity of a series of new N1-methyl, N1-allyl, N1-2-chloroethyl and N1-propargyl urea derivatives of…”
Get more information